IL33 and renal carcinoma: In addition, we included the soluble IL33 decoy receptor IL33Rα because this biomarker should also be regarded as an acute phase protein (i.e., a systemic marker of inflammation) [18,19,20,21], but we did not include IL33 itself because it is produced by renal cancer cells and its local release is likely more important [51].